Alvelestat's Phase 3 Bet: Oral Convenience vs. Unvalidated Imaging Endpoint and AAT's Payer Ceiling

Sentynl Licenses Mereo's Alvelestat for Rare Lung Disease

Sentynl Therapeutics secured an exclusive option to commercialize Mereo BioPharma’s investigational therapy, alvelestat, in the U.S. for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The agreement involves Sentynl paying an undisclosed fee for the option, with a potential $40 million covering upfront and R&D payments upon exercise, leading up to NDA submission. Additionally, Mereo stands to receive up to $435 million in milestones and double-digit tiered royalties on net U.S. sales. This deal will enable Mereo to initiate Phase 3 development for alvelestat, targeting an early 2027 launch for the oral neutrophil elastase inhibitor.

• Financial Terms of the Agreement: Sentynl Therapeutics' agreement with Mereo BioPharma includes an exclusive option for U.S. commercialization of alvelestat. If exercised, Sentynl will pay $40 million covering upfront and R&D costs until NDA submission. The deal also features up to $435 million in potential milestone payments and double-digit tiered royalties on net U.S. sales, totaling a potential value of up to $475 million for Mereo.
• Alvelestat's Profile and Clinical Data: Alvelestat is an oral small molecule designed to block the neutrophil elastase enzyme, implicated in lung tissue destruction in AATD-LD. This rare genetic respiratory disorder affects 50,000 to 80,000 patients in the U.S. Phase 2 data, released in May 2023, demonstrated significant efficacy, showing an 83.5% reduction in neutrophil elastase activity at a lower dose and 93.3% suppression at a higher dose, both superior to placebo.
• Development Pathway and Regulatory Alignment: The licensing deal is crucial for advancing alvelestat into late-stage development. Mereo BioPharma had previously aligned with the FDA on the Phase 3 design for the asset and was seeking partners. With Sentynl's support, the Phase 3 program for alvelestat is now set to launch early in 2027, moving the investigational therapy closer to potential market availability for AATD-LD patients.

Alvelestat's Competitive Edge: Other Neutrophil Elastase Inhibitors

AZD9668 is a neutrophil elastase (NE) inhibitor sharing the same mechanism of action as alvelestat, and has been evaluated across multiple respiratory indications in randomised controlled trials. All three AZD9668 studies employed a randomised, double-blind, placebo-controlled, parallel-group design — consistent with the intervention model used in alvelestat's pivotal trials (ATALANTa and ASTRAEUS) in alpha-1 antitrypsin deficiency.

Alvelestat Deal: A New Chapter for Oral AATD Therapy?

The recent agreement between Sentynl Therapeutics and Mereo BioPharma for alvelestat marks a pivotal moment for patients living with alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). This rare genetic disorder, characterized by a critical imbalance between proteases and anti-proteases, currently relies heavily on intravenous augmentation therapy, which, while beneficial, presents logistical challenges for patients. The prospect of an oral neutrophil elastase inhibitor like alvelestat offers a compelling alternative or adjunct, potentially enhancing patient convenience and adherence.

For Mereo, this deal provides the financial runway and a dedicated U.S. commercial partner to propel alvelestat into Phase 3 trials, significantly de-risking the asset's development. Sentynl, in turn, gains a strategic entry into the orphan disease space with a novel mechanism of action. The drug's ability to suppress neutrophil elastase and reduce disease activity biomarkers at the 240 mg twice-daily dose is encouraging, particularly given the historical challenges faced by this drug class in broader chronic obstructive pulmonary disease (COPD) populations.

However, the path forward is not without its considerations. The literature indicates that other neutrophil elastase inhibitors, such as AZD9668, did not translate biomarker improvements into significant clinical benefits in COPD. This raises a critical question for alvelestat: will its biomarker efficacy translate into tangible improvements in lung function, exacerbation rates, and quality of life, which are the ultimate measures of success for patients and regulators? Furthermore, the higher, more effective dose of alvelestat was associated with headache, a common adverse event that could influence long-term tolerability and adherence in a chronic treatment regimen. As alvelestat progresses, the focus will undoubtedly shift to demonstrating robust clinical endpoint data to solidify its position as a transformative therapy for AATD-LD.